Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Feb;69(1):1–15. doi: 10.1016/j.curtheres.2008.02.003

Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study

Roberto Fogari 1,1, Annalisa Zoppi 1, Amedeo Mugellini 1, Paola Preti 1, Maurizio Destro 1, Andrea Rinaldi 1, Giuseppe Derosa 1
PMCID: PMC3969955  PMID: 24692778

Abstract

Background:The potential combinations of antihypertensive agents are many, and making rational choices depends on the characteristics of each drug and on their complementary mechanisms of action.

Objective: The aim of this study was to evaluate the effectiveness of adding hydrochlorothiazide (HCTZ) 12.5 mg to olmesartan 20 mg or telmisartan 80 mg on blood pressure (BP) in patients with moderate hypertension.

Methods: Consecutive outpatients at the Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Pavia, Italy, of both sexes aged 39 to 75 years were considered eligible for enrollment if they had a sitting diastolic BP (DBP) ->99 mm Hg and <110 mm Hg at the end of an initial 2-week washout period. Patients were random- ized to olmesartan 20 mg QD or telmisartan 80 mg QD according to a prospective, open-label, blinded end point, parallel-arm design. After 8 weeks of monotherapy, patients whose BP was not controlled (DBP ->90 mm Hg) received HCTZ 12.5 mg QD for 8 additional weeks. Clinical and ambulatory BPs were measured at the end of the washout period and at the end of both treatment periods. Adverse events (AEs) were recorded from spontaneous reports and direct inquiry from investigators.

Results: One hundred forty-five patients, all of whom were white, were recruited for the study. After the initial washout period, 13 patients did not meet the inclusion criteria and 6 refused to continue. A total of 126 white patients (69 men, 57 women; mean [SD] age, 60.2 [11.6] years) were randomized to receive monotherapy. Of these, 35 patients (56%) in the olmesartan group and 33 (52%) in the telmisartan group had previously received antihypertensive therapy. At the end of monotherapy, the 52 patients in the olmesartan group and the 49 patients in the telmisartan treatment group who were still in the study and had their BP inadequately controlled by treatment had HCTZ 12.5 mg QD added to their treatment regimen. Both combinations induced a greater ambulatory mean (SD) systolic BP (SBP) and DBP reduction than monothera- py (SBP: 145.3 [6.1] in the olmesartan group and 140.1 [6.4] in the telmisartan group, P < 0.05; DBP: 88.1 [5.1] in the olmesartan group and 84.9 [4.9] in the telmisartan group, P < 0.05). The mean (SD) reduction from baseline in the telmisartan/HCTZ-treated patients (21.5 [10.1]/14.6 [5.2] mm Hg for 24 hours, 21.8 [10.2]/14.9 [5.2] mm Hg for daytime, and 20.4 [10.3]/13.7 [5.9] mm Hg for nighttime; all, P < 0.001 vs baseline) was significantly greater than that observed in the olmesartan/HCTZ-treated patients (18.8 [9.8]/12.3 [4.9] mm Hg for 24 hours, 19.3 [9.8]/12.8 [4.9] mm Hg for daytime, and 17.4 [10.2]/10.6 [5.5] mm Hg for nighttime; all, P < 0.001 vs baseline), with a significant difference between the 2 treatment groups (P < 0.01). Compared with mono- therapy, the add-on effect of HCTZ 12.5 mg QD administration was significantly greater in the telmisartan group than in the olmesartan group (P < 0.05); the differ- ence being more evident for nighttime BP values (SBP, P 0.031; DBP, P 0.025). Reported AEs were similar in the olmesartan/HCTZ and the telmisartan/HCTZ groups (4 patients [7%] vs 3 patients [6%]).

Conclusion: The addition of HCTZ 12.5 mg to telmisartan 80 mg monothera- py was associated with greater BP reduction than the addition of the same dose of HCTZ to olmesartan 20 nag monotherapy in these patients previously uncontrolled on monotherapy.

Key words: hydrochlorothiazide, telmisartan, olmesartan, hypertension

Full Text

The Full Text of this article is available as a PDF (787.7 KB).

References

  • 1.Chobanian AV, Bakris GL, Black HR, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197] JAMA. 2003;289:2560–2572. doi: 10.1001/jama.289.19.2560. [DOI] [PubMed] [Google Scholar]
  • 2.2003 European Society of Hypertension-European Society of Cardidogy guidelines for the management of arterial hypertension J Hypertens. 2003;21:1011–1053. doi: 10.1097/00004872-200306000-00001. [DOI] [PubMed] [Google Scholar]
  • 3.Turnbull F, for the Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure lowering regimens on major cardiovascular events: Results of prospectively- designed overviews of randomised trials. Lancet. 2003;362:1527–1535. doi: 10.1016/s0140-6736(03)14739-3. [DOI] [PubMed] [Google Scholar]
  • 4.Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055–1076. doi: 10.1097/00004872-200306000-00002. [DOI] [PubMed] [Google Scholar]
  • 5.Hansson L, Zanchetti A, Carruthers SG, for the HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. doi: 10.1016/s0140-6736(98)04311-6. [DOI] [PubMed] [Google Scholar]
  • 6.UK Prospective Diabetes Study Group Tight blood pressure contrd and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713. [PMC free article] [PubMed] [Google Scholar]
  • 7.Yusuf S, Sleight P, Pogue J, for the Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342:1376 and N Engl J Med. 2000;342:748] N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]
  • 8.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–2997. doi: 10.1001/jama.288.23.2981. [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196] [DOI] [PubMed] [Google Scholar]
  • 9.Moser M, Black HR. The rde of combination therapy in the treatment of hypertension. Amy Hypertens. 1998;11:73S–78S. doi: 10.1016/s0895-7061(98)00060-0. [DOI] [PubMed] [Google Scholar]
  • 10.Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs. 2002;62:443–462. doi: 10.2165/00003495-200262030-00003. [DOI] [PubMed] [Google Scholar]
  • 11.Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43–50. doi: 10.1586/14779072.1.1.43. [DOI] [PubMed] [Google Scholar]
  • 12.Palatini P. Combination therapy in the management of hypertension: Focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens. 2005;7:96–101. doi: 10.1111/j.1524-6175.2005.03793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kjeldsen SE, Os I, HOieggen A. Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Amy Cardiovasc Drugs. 2005;5:17–22. doi: 10.2165/00129784-200505010-00003. [DOI] [PubMed] [Google Scholar]
  • 14.McInnes GT, O'Kane KP, Istad H. Comparison of the ATl-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000;14:263–269. doi: 10.1038/sj.jhh.1000997. [DOI] [PubMed] [Google Scholar]
  • 15.Palatini P, Mugellini A, Spagnudo V, for the Investigators Group Comparison of the effects on 24-h ambulatory blood pressure ofvalsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study) Blood Press Monit. 2004;9:91–97. doi: 10.1097/00126097-200404000-00006. [DOI] [PubMed] [Google Scholar]
  • 16.Rump LC, Ambrosioni E, Burnier M. Initial combination therapy with olmesartan/ hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens. 2006;20:299–301. doi: 10.1038/sj.jhh.1001984. [DOI] [PubMed] [Google Scholar]
  • 17.Hansson L, Hedner T, Dahlöf B. Prospective, randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1:113–119. doi: 10.3109/08037059209077502. [DOI] [PubMed] [Google Scholar]
  • 18.Groppelli A, Omboni S, Ravogli A. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens Suppl. 1991;9:S334–S335. [PubMed] [Google Scholar]
  • 19.Parati G, Bosi S, Castellano M, Guidelines for 24-h non-invasive ambulatory blood pressure monitoring Report from a working group of the Italian Society of Hypertension. High Blood Press. 1995;4:168–174. [Google Scholar]
  • 20.Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: Methodological aspects. J Hypertens. 1995;13:1105–1112. doi: 10.1097/00004872-199510000-00005. [DOI] [PubMed] [Google Scholar]
  • 21.Rose M, McMahon FC. Some problems with antihypertensive drug studies in the context of the new guidelines. Amy Hypertens. 1990;3:151–155. doi: 10.1093/ajh/3.2.151. [DOI] [PubMed] [Google Scholar]
  • 22.Rizzoni D, Castellano M, Muiesan ML. Beyond trough:peak ratio: A new index of the smoothness of the antihypertensive effect of a drug. High Blood Press. 1997;6:110–115. [Google Scholar]
  • 23.Parati G, Omboni S, Rizzoni D. The Smoothness Index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685–1691. doi: 10.1097/00004872-199816110-00016. [DOI] [PubMed] [Google Scholar]
  • 24.Freytag F, Schelling A, Meinicke T, Deichsel G, for the Telmisartan Hypertension Experience in a Randomized European Study Versus Atenold Study Group Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study. Clin Thef. 2001;23:108–123. doi: 10.1016/s0149-2918(01)80034-5. [DOI] [PubMed] [Google Scholar]
  • 25.McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2001;23:833–850. doi: 10.1016/s0149-2918(01)80072-2. [DOI] [PubMed] [Google Scholar]
  • 26.Schmieder RE. Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. Expert Opin Pharmacother. 2004;5:2303–2310. doi: 10.1517/14656566.5.11.2303. [DOI] [PubMed] [Google Scholar]
  • 27.Maillard M, Burnier M. Telmisartan/hydrochlorothiazide: A new fixed dose combination. Expert Rev Cardiovasc Ther. 2005;3:375–386. doi: 10.1586/14779072.3.3.375. [DOI] [PubMed] [Google Scholar]
  • 28.Chrysant SG, Chrysant GS. Antihypertensive efficacy of dmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother. 2004;5:657–667. doi: 10.1517/14656566.5.3.657. [DOI] [PubMed] [Google Scholar]
  • 29.Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to dmesartan dose dependently improves 24-h blood pressure and response rates in mild-to moderate hypertension. J Hypertens. 2005;23:2083–2092. doi: 10.1097/01.hjh.0000186022.74245.01. [DOI] [PubMed] [Google Scholar]
  • 30.Fogari R, Zoppi A, Mugellini A. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately contrdled by monotherapy. Adv Ther. 2006;23:680–695. doi: 10.1007/BF02850307. [DOI] [PubMed] [Google Scholar]
  • 31.McClellan KJ, Markham A. Telmisartan. Drugs. 1998;56:1039–1044. doi: 10.2165/00003495-199856060-00007. [DOI] [PubMed] [Google Scholar]
  • 32.Nussberger J, Koike H. Antagonizing the angiotensin II subtype I receptor: A focus on dmesartan medoxomil. Clin Thef. 2004;26:A12–A20. doi: 10.1016/s0149-2918(04)90141-5. [DOI] [PubMed] [Google Scholar]
  • 33.Turnbull F. Effectsofdifferent blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535. doi: 10.1016/s0140-6736(03)14739-3. [DOI] [PubMed] [Google Scholar]
  • 34.Turnbull F, Neal B, Algert C. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Ned. 2005;165:1410–1419. doi: 10.1001/archinte.165.12.1410. [DOI] [PubMed] [Google Scholar]
  • 35.Mancia G. Role of outcome trials in providing information on antihypertensive treatment: Importance and limitations. Am J Hypertens. 2006;19:1–7. doi: 10.1016/j.amjhyper.2005.10.009. [DOI] [PubMed] [Google Scholar]
  • 36.Liu L, Zhang Y, Liu G. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–2172. doi: 10.1097/01.hjh.0000194120.42722.ac. [DOI] [PubMed] [Google Scholar]
  • 37.Lithell H, Hansson L, Skoog I, for the SCOPE Study Group The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–886. doi: 10.1097/00004872-200305000-00011. [DOI] [PubMed] [Google Scholar]
  • 38.Meredith PA. Role of trough to peak efficacy in the evaluation of antihypertensive therapy. J Hypertens Suppl. 1998;16:S59–S64. [PubMed] [Google Scholar]
  • 39.Palatini P, Penzo M, Racioppa A. Clinical relevance of nighttime blood pressure and day- time blood pressure variability. Arch Intern Ned. 1992;152:1855–1860. [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES